oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2020-19-1-119-125oncotomsk-1331Research ArticleОБЗОРЫREVIEWSСОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О КОМБИНАЦИИ ЛУЧЕВОЙ ТЕРАПИИ С АНТИАНГИОГЕННЫМИ ПРЕПАРАТАМИ В ЛЕЧЕНИИ БОЛЬНЫХ С МЕТАСТАТИЧЕСКИМ ПОРАЖЕНИЕМ ГОЛОВНОГО МОЗГАMODERN IDEAS ABOUT THE COMBINATION OF RADIATION THERAPY WITH ANTIANGIOGENIC DRUGS IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASEShttps://orcid.org/0000-0003-3061-6108КитО. И.KitO. I.

доктор медицинских наук, профессор, член‑корреспондент РАН, генеральный директор

SPIN‑код: 1728‑0329. Researcher ID (WOS): U‑2241‑2017. Author ID (Scopus): 55994103100Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, Professor, Corresponding Member of the Russian Academy of Sciences, General Director

Researcher ID (WOS): U‑2241‑2017. Author ID (Scopus): 55994103100

ГеворкянЭ. Ю.GevorkianE. Yu.

6th year student, Faculty of Medicine

https://orcid.org/0000-0001-8511-7280СидоренкоЮ. С.SidorenkoYu. S.

доктор медицинских наук, профессор, академик РАН, заведующий отделом опухолей репродуктивной системы, 

SPIN‑код: 8341‑5407. Author ID (Scopus): 6603967956Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, Professor, Full Member of the Russian Academy of Sciences, Head of the Department of Tumors of the Reproductive System 

Author ID (Scopus): 6603967956

https://orcid.org/0000-0003-1405-8329ВошедскийВ. И.VoshedskiyV. I.

врач‑радиотерапевт

Researcher ID (WOS): Q‑6122‑2019 Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, Radiologist

Researcher ID (WOS): Q‑6122‑2019

 

vvoshed@mail.ruДженковаЕ. А.GenkovaE. A.

доктор биологических наук, доцент, учёный секретарь

SPIN‑код: 6206‑6222. Author ID (Scopus): 6507889745. Researcher ID (WOS): K‑9622‑2014 Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

DSc, Associate Professor

Author ID (Scopus): 6507889745. Researcher ID (WOS): K‑9622‑2014

ШапошниковА. В.ShaposhnikovA. V.

доктор медицинских наук, профессор, главный научный сотрудник торакоабдоминального отдела

SPIN‑код: 8756‑9438. Author ID (Scopus): 7005752070 Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, Professor, Leading Researcher, Thoracoabdominal Department,

Author ID (Scopus): 7005752070

СакунП. Г.SakunP. G.

кандидат медицинских наук, врач‑радиотерапевт

SPIN‑код: 3790‑9852. AuthorID (РИНЦ): 734600. Author ID (Scopus): 56531945400 Россия, г. Ростов-на-Дону, 344037, ул. 14-я линия, 63

MD, PhD, Radiologist

Author ID (Scopus): 56531945400

ФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения Российской ФедерацииРоссияRostov Research Institute of Oncology, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)»РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202002032020191119125Copyright © Кит О.И., Геворкян Э.Ю., Сидоренко Ю.С., Вошедский В.И., Дженкова Е.А., Шапошников А.В., Сакун П.Г., 20202020Кит О.И., Геворкян Э.Ю., Сидоренко Ю.С., Вошедский В.И., Дженкова Е.А., Шапошников А.В., Сакун П.Г.Kit O.I., Gevorkian E.Y., Sidorenko Y.S., Voshedskiy V.I., Genkova E.A., Shaposhnikov A.V., Sakun P.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1331

Цель исследования – обобщение имеющихся данных о комбинации лучевой терапии с антиангиогенными препаратами в лечении больных с метастатическим поражением головного мозга.

Материал и методы

Материал и методы. Поиск литературы производился в системах Medline, Cochrane Library, Elibrary, PubMed, включались публикации, характеризующие современные возможности лучевой терапии и результаты ее применения для лечения больных с метастатическим поражением головного мозга как в самостоятельном  варианте, так и в комбинации с антиангиогенными препаратами.

Результаты

Результаты. В настоящее время существуют различные варианты комбинации лучевой терапии с антиангиогенными препаратами. Полученные результаты свидетельствуют о более высокой эффективности комбинированного применения радиотерапии и антиангиогенных препаратов для лечения больных с метастатическим поражением головного мозга по сравнению с лучевой терапией в самостоятельном варианте.

Заключение

Заключение. Лечение больных с метастатическим поражением головного мозга является чрезвычайно сложной задачей в современной клинической практике. Разнообразие возможных терапевтических подходов требует мультидисциплинарного подхода к данной проблеме.

Purpose of the study

Purpose of the study: to analyze available data on the combination of radiation therapy with antiangiogenic drugs in the treatment of patients with brain metastases.

Material and methods

Material and methods. The search for relevant sources was carried out using Medline, Cochrane Library, Elibrary, PubMed databases concerning publications describing the role of radiation therapy in the treatment of patients with brain metastases. results. To date, there are various options for the combination of radiation therapy with antiangiogenic drugs.

The results obtained indicate that radiotherapy combined with antiangiogenic drugs is more efficient in the treatment of patients with brain metastases than radiotherapy used alone. Conclusion. Treatment of patients with brain metastases remains extremely challenging and requires a multidisciplinary team approach.

метастатическое поражение головного мозгалучевая терапиярадиохирургиябевацизумабкомплексная терапияантиангиогенные препаратыbrain metastasesradiation therapyradiosurgeryantiangiogenic drugsReferencesГоланов А.В., Банов С.M., Ветлова Е.P. Метастатическое поражение головного мозга: изменение парадигмы лучевого лечения. Вопросы онкологии. 2015; 61(4): 530–545.Golanov A.V., Banov S.M., Vetlova E.R. Metastatic brain lesion paradigm shift in radiation therapy. Problems of Oncology. 2015; 61(4): 530–545. (in Russian).Kocher M., Wittig A., Piroth M.D., Treuer H., Seegenschmiedt H., Ruge M., Grosu A.L., Guckenberger M. Stereotactic radiosurgery for treatment of brain metastases. Strahlenther Onkol. 2014 Jun; 190(6): 521–32. doi: 10.1007/s00066‑014‑0648‑7.Kocher M., Wittig A., Piroth M.D., Treuer H., Seegenschmiedt H., Ruge M., Grosu A.L., Guckenberger M. Stereotactic radiosurgery for treatment of brain metastases. Strahlenther Onkol. 2014 Jun; 190(6): 521–32. doi: 10.1007/s00066‑014‑0648‑7.Sahgal A., Soliman H., Larson D.A. Whole‑brain radiation therapy of brain metastasis. Prog Neurol Surg. 2012; 25: 82–95. doi: 10.1159/000331179.Sahgal A., Soliman H., Larson D.A. Whole‑brain radiation therapy of brain metastasis. Prog Neurol Surg. 2012; 25: 82–95. doi: 10.1159/000331179.Ebi J., Sato H., Nakajima M., Shishido F. Incidence of leukoencephalopathy after whole‑brain radiation therapy for brain metastases. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5): 1212–7. doi: 10.1016/j.ijrobp.2012.09.025.Ebi J., Sato H., Nakajima M., Shishido F. Incidence of leukoencephalopathy after whole‑brain radiation therapy for brain metastases. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85(5): 1212–7. doi: 10.1016/j.ijrobp.2012.09.025.Lippitz B., Lindquist C., Paddick I., Peterson D., O'Neill K., Beaney R. Stereotactic radiosurgery in the treatment of brain metastases. Cancer Treat Rev. 2014 Feb; 40(1): 48–59. doi: 10.1016/j.ctrv.2013.05.002.Lippitz B., Lindquist C., Paddick I., Peterson D., O'Neill K., Beaney R. Stereotactic radiosurgery in the treatment of brain metastases. Cancer Treat Rev. 2014 Feb; 40(1): 48–59. doi: 10.1016/j.ctrv.2013.05.002.Голанов А.В., Банов С.М., Ильялов С.Р., Ветлова Е.Р., Костюченко В.В. Современные подходы к лучевому лечению метастатического поражения головного мозга. Злокачественные опухоли. 2014; 3(10): 137–140.Golanov A.V., Banov S.M., Ilyalov S.R., Vetlova E.R., Kostyuchenko V.V. Modern approaches to radiation treatment of metastatic brain damage. Malignant tumors. 2014; 3(10): 137–140. (in Russian).Канаев С.В., Гиршович М.М., Мельник Ю.С. Клинический опыт радиохирургического лечения метастатического поражения головного мозга при злокачественных новообразованиях. Вопросы онкологии. 2016; 62(2): 258–264.Kanaev S.V., Girshovich M.M., Melnik Yu.S. Clinical experience of radiosurgical treatment for metastatic brain lesion in malignant tumors. Problems of Oncology. 2016; 62(2): 258–264. (in Russian).Yamamoto M., Kawabe T., Sato Y., Higuchi Y., Nariai T., Watanabe S., Kasuya H. Stereotactic radiosurgery for patients with multiple brain metastases: a case‑matched study comparing treatment results for patients with 29 versus 10 or more tumors. J Neurosurg. 2014 Dec; 121 Suppl: 16–25. doi: 10.3171/2014.8.GKS141421.Yamamoto M., Kawabe T., Sato Y., Higuchi Y., Nariai T., Watanabe S., Kasuya H. Stereotactic radiosurgery for patients with multiple brain metastases: a case‑matched study comparing treatment results for patients with 29 versus 10 or more tumors. J Neurosurg. 2014 Dec; 121 Suppl: 16–25. doi: 10.3171/2014.8.GKS141421.Голанов А.В., Банов С.М., Ильялов С.Р., Трунин Ю.Ю., Маряшев С.А., Ветлова Е.Р., Осинов И.К., Костюченко В.В., Далечина А.В., Дургарян А.А. Радиохирургическое лечение метастазов в головной мозг. Факторы прогноза общей выживаемости и интракраниальных рецидивов. Вопросы нейрохирургии им. Н.Н. Бурденко. 2016; 80(2): 35–46.Golanov A.V., Banov S.M., Il’yalov S.R., Trunin Yu.Yu., Maryashev S.A., Vetlova E.R., Osinov I.K., Kostyuchenko V.V., Dalechina A.V., Durgaryan A.A. Overall survival and intracranial relapse in patients with brain metastases after gamma knife radiosurgery alone. Problems of neurosurgery named after N.N. Burdenko. 2016; 80(2): 35–46. (in Russian).Preusser M., Winkler F., Collette L., Haller S., Marreaud S., Soffietti R., Klein M., Reijneveld J.C., Tonn J.C., Baumert B.G., Mulvenna P., Schadendorf D., Duchnowska R., Berghoff A.S., Lin N., Cameron D.A., Belkacemi Y., Jassem J., Weber D.C. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012 Dec; 48(18): 3439–47. doi: 10.1016/j.ejca.2012.07.002.Preusser M., Winkler F., Collette L., Haller S., Marreaud S., Soffietti R., Klein M., Reijneveld J.C., Tonn J.C., Baumert B.G., Mulvenna P., Schadendorf D., Duchnowska R., Berghoff A.S., Lin N., Cameron D.A., Belkacemi Y., Jassem J., Weber D.C. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer. 2012 Dec; 48(18): 3439–47. doi: 10.1016/j.ejca.2012.07.002.Berghoff A.S., Rajky O., Winkler F., Bartsch R., Furtner J., Hainfellner J.A., Goodman S.L., Weller M., Schittenhelm J., Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro Oncol. 2013 Dec; 15(12): 1664–72. doi: 10.1093/neuonc/not112.Berghoff A.S., Rajky O., Winkler F., Bartsch R., Furtner J., Hainfellner J.A., Goodman S.L., Weller M., Schittenhelm J., Preusser M. Invasion patterns in brain metastases of solid cancers. Neuro Oncol. 2013 Dec; 15(12): 1664–72. doi: 10.1093/neuonc/not112.Berghoff A.S., Ilhan-Mutlu A., Dinhof C., Magerle M., Hackl M., Widhalm G., Hainfellner J.A., Dieckmann K., Pichler J., Hutterer M., Melchardt T., Bartsch R., Zielinski C.C., Birner P., Preusser M. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol. 2015 Feb; 41(2): e41–55. doi: 10.1111/nan.12185.Berghoff A.S., Ilhan-Mutlu A., Dinhof C., Magerle M., Hackl M., Widhalm G., Hainfellner J.A., Dieckmann K., Pichler J., Hutterer M., Melchardt T., Bartsch R., Zielinski C.C., Birner P., Preusser M. Differential role of angiogenesis and tumour cell proliferation in brain metastases according to primary tumour type: analysis of 639 cases. Neuropathol Appl Neurobiol. 2015 Feb; 41(2): e41–55. doi: 10.1111/nan.12185.Ilhan-Mutlu A., Osswald M., Liao Y., Gömmel M., Reck M., Miles D., Mariani P., Gianni L., Lutiger B., Nendel V., Srock S., Perez-Moreno P., Thorsen F., von Baumgarten L., Preusser M., Wick W., Winkler F. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther. 2016; 15(4): 702–10. doi: 10.1158/1535‑7163.MCT‑15‑0582.Ilhan-Mutlu A., Osswald M., Liao Y., Gömmel M., Reck M., Miles D., Mariani P., Gianni L., Lutiger B., Nendel V., Srock S., Perez-Moreno P., Thorsen F., von Baumgarten L., Preusser M., Wick W., Winkler F. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther. 2016; 15(4): 702–10. doi: 10.1158/1535‑7163.MCT‑15‑0582.Bohn K.A., Adkins C.E., Nounou M.I., Lockman P.R. Inhibition of VEGF and angiopoietin‑2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017; 8: 193. doi: 10.3389/fphar.2017.00193.Bohn K.A., Adkins C.E., Nounou M.I., Lockman P.R. Inhibition of VEGF and angiopoietin‑2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017; 8: 193. doi: 10.3389/fphar.2017.00193.Vanhuyse M., Penel N., Caty A., Fumagalli I., Alt M., Zini L., Adenis A. Do anti‑angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bull Cancer. 2012; 99(12): 100–6. doi: 10.1684/bdc.2012.1672.Bohn K.A., Adkins C.E., Nounou M.I., Lockman P.R. Inhibition of VEGF and angiopoietin‑2 to reduce brain metastases of breast cancer burden. Front Pharmacol. 2017; 8: 193. doi: 10.3389/fphar.2017.00193.Letarte N., Bressler L.R., Villano J.L. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013 Jun; 71(6): 1561–5. doi: 10.1007/s00280‑013‑2155‑4.Vanhuyse M., Penel N., Caty A., Fumagalli I., Alt M., Zini L., Adenis A. Do anti‑angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bull Cancer. 2012; 99(12): 100–6. doi: 10.1684/bdc.2012.1672.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010; 16(1): 269–78. doi: 10.1158/1078‑0432.CCR‑09‑2439.Vanhuyse M., Penel N., Caty A., Fumagalli I., Alt M., Zini L., Adenis A. Do anti‑angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bull Cancer. 2012; 99(12): 100–6. doi: 10.1684/bdc.2012.1672.Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., Akerley W. Safety of bevacizumab in patients with non‑small‑cell lung cancer and brain metastases. J Clin Oncol. 2009 Nov 1; 27(31): 5255–61. doi: 10.1200/JCO.2009.22.0616.Letarte N., Bressler L.R., Villano J.L. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013 Jun; 71(6): 1561–5. doi: 10.1007/s00280‑013‑2155‑4.Bennouna J., Falchero L., Schott R., Bonnetain F., Coudert M., Ben Hadj Yahia B., Chouaid C. Bevacizumab in combination with platinumbased chemotherapy in patients with advanced non‑squamous non‑small cell lung cancer with or without brain metastases: a French cohort study (EOLE). Oncology. 2018; 94(1): 55–64. doi: 10.1159/000480702.Letarte N., Bressler L.R., Villano J.L. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol. 2013 Jun; 71(6): 1561–5. doi: 10.1007/s00280‑013‑2155‑4.Besse B., Le Moulec S., Mazières J., Senellart H., Barlesi F., Chouaid C., Dansin E., Bérard H., Falchero L., Gervais R., Robinet G., Ruppert A.M., Schott R., Léna H., Clément-Duchêne C., Quantin X., Souquet P.J., Trédaniel J., Moro-Sibilot D., Pérol M., Madroszyk A.C., Soria J.C. Bevacizumab in patients with nonsquamous non‑small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015; 21(8): 1896–903. doi: 10.1158/1078‑0432.CCR‑14‑2082.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010; 16(1): 269–78. doi: 10.1158/1078‑0432.CCR‑09‑2439.Stefanou D., Stamatopoulou S., Sakellaropoulou A., Akakios G., Gkiaouraki M., Gkeka D., Prevezanou M., Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first‑line treatment of non‑small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett. 2016 Dec; 12(6): 4635–4642. doi: 10.3892/ol.2016.5268.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010; 16(1): 269–78. doi: 10.1158/1078‑0432.CCR‑09‑2439.Labidi S.I., Bachelot T., Ray-Coquard I., Mosbah K., Treilleux I., Fayette J., Favier B., Galy G., Blay J.Y., Guastalla J.P. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: acaseseries. Clin Breast Cancer. 2009 May; 9(2): 118–21. doi: 10.3816/CBC.2009.n.021.Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., Akerley W. Safety of bevacizumab in patients with non‑small‑cell lung cancer and brain metastases. J Clin Oncol. 2009 Nov 1; 27(31): 5255–61. doi: 10.1200/JCO.2009.22.0616.Soffietti R., Abacioglu U., Baumert B., Combs S.E., Kinhult S., Kros J.M., Marosi C., Metellus P., Radbruch A., Villa Freixa S.S., Brada M., Carapella C.M., Preusser M., Le Rhun E., Rudà R., Tonn J.C., Weber D.C., Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro‑Oncology (EANO). Neuro Oncol. 2017 Feb 1; 19(2): 162–174. doi: 10.1093/neuonc/now241.Socinski M.A., Langer C.J., Huang J.E., Kolb M.M., Compton P., Wang L., Akerley W. Safety of bevacizumab in patients with non‑small‑cell lung cancer and brain metastases. J Clin Oncol. 2009 Nov 1; 27(31): 5255–61. doi: 10.1200/JCO.2009.22.0616.Berghoff A.S., Schur S., Füreder L.M., Gatterbauer B., Dieckmann K., Widhalm G., Hainfellner J., Zielinski C.C., Birner P., Bartsch R., Preusser M. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016 Mar 16; 1(2): e000024. doi: 10.1136/esmoopen‑2015‑000024.Bennouna J., Falchero L., Schott R., Bonnetain F., Coudert M., Ben Hadj Yahia B., Chouaid C. Bevacizumab in combination with platinumbased chemotherapy in patients with advanced non‑squamous non‑small cell lung cancer with or without brain metastases: a French cohort study (EOLE). Oncology. 2018; 94(1): 55–64. doi: 10.1159/000480702.Jeon Y.S., Koh Y.C., Song S.W., Cho J., Lim S.D. Palliative resection of metastatic brain tumors previously treated by stereotactic radiosurgery. Brain Tumor Res Treat. 2016 Oct; 4(2): 116–123.Bennouna J., Falchero L., Schott R., Bonnetain F., Coudert M., Ben Hadj Yahia B., Chouaid C. Bevacizumab in combination with platinumbased chemotherapy in patients with advanced non‑squamous non‑small cell lung cancer with or without brain metastases: a French cohort study (EOLE). Oncology. 2018; 94(1): 55–64. doi: 10.1159/000480702.Glitza I.C., Guha-Thakurta N., D'Souza N.M., Amaria R.N., McGovern S.L., Rao G., Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 Dec; 27(6): 580–584. doi: 10.1097/CMR.0000000000000389.Besse B., Le Moulec S., Mazières J., Senellart H., Barlesi F., Chouaid C., Dansin E., Bérard H., Falchero L., Gervais R., Robinet G., Ruppert A.M., Schott R., Léna H., Clément-Duchêne C., Quantin X., Souquet P.J., Trédaniel J., Moro-Sibilot D., Pérol M., Madroszyk A.C., Soria J.C. Bevacizumab in patients with nonsquamous non‑small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015; 21(8): 1896–903. doi: 10.1158/1078‑0432.CCR‑14‑2082.Delishaj D., Ursino S., Pasqualetti F., Cristaudo A., Cosottini M., Fabrini M.G., Paiar F. Bevacizumab for the treatment of radiation‑induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017 Apr; 9(4): 273–280. doi: 10.14740/jocmr2936e.Besse B., Le Moulec S., Mazières J., Senellart H., Barlesi F., Chouaid C., Dansin E., Bérard H., Falchero L., Gervais R., Robinet G., Ruppert A.M., Schott R., Léna H., Clément-Duchêne C., Quantin X., Souquet P.J., Trédaniel J., Moro-Sibilot D., Pérol M., Madroszyk A.C., Soria J.C. Bevacizumab in patients with nonsquamous non‑small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015; 21(8): 1896–903. doi: 10.1158/1078‑0432.CCR‑14‑2082.Berghoff A.S., Preusser M. Anti‑angiogenic therapies in brain metastases. Memo. 2018; 11(1): 14–17. doi: 10.1007/s12254‑018‑0384‑2.Stefanou D., Stamatopoulou S., Sakellaropoulou A., Akakios G., Gkiaouraki M., Gkeka D., Prevezanou M., Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first‑line treatment of non‑small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett. 2016 Dec; 12(6): 4635–4642. doi: 10.3892/ol.2016.5268.Berghoff A.S., Sax C., Klein M., Furtner J., Dieckmann K., Gatterbauer B., Widhalm G., Rudas M., Zielinski C.C., Bartsch R., Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain‑ metastatic breast cancer: a case report. Breast Care (Basel). 2014 May; 9(2): 134–6. doi: 10.1159/000360930.Stefanou D., Stamatopoulou S., Sakellaropoulou A., Akakios G., Gkiaouraki M., Gkeka D., Prevezanou M., Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first‑line treatment of non‑small cell lung cancer patients: focus on patients with brain metastases. Oncol Lett. 2016 Dec; 12(6): 4635–4642. doi: 10.3892/ol.2016.5268.Slotman B.J., Mauer M.E., Bottomley A., Faivre-Finn C., Kramer G.W., Rankin E.M., Snee M., Hatton M., Postmus P.E., Collette L., Senan S. Prophylactic Cranial Irradiation in Extensive Disease Small‑Cell Lung Cancer. J Clin Oncol. 2009 Jan 1; 27(1): 78–84. doi: 10.1200/JCO.2008.17.0746.Labidi S.I., Bachelot T., Ray-Coquard I., Mosbah K., Treilleux I., Fayette J., Favier B., Galy G., Blay J.Y., Guastalla J.P. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: acaseseries. Clin Breast Cancer. 2009 May; 9(2): 118–21. doi: 10.3816/CBC.2009.n.021.Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E.2nd, Peters K.B., Allen K., Hoang J.K., Chang Z., Craciunescu O., Vredenburgh J.J., Friedman H.S., Kirkpatrick J.P. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5): 873–9. doi: 10.1016/j.ijrobp.2013.04.029.Labidi S.I., Bachelot T., Ray-Coquard I., Mosbah K., Treilleux I., Fayette J., Favier B., Galy G., Blay J.Y., Guastalla J.P. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: acaseseries. Clin Breast Cancer. 2009 May; 9(2): 118–21. doi: 10.3816/CBC.2009.n.021.Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E. 2nd, McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1): 63–70. doi: 10.1007/s11060‑012‑0861‑0.Soffietti R., Abacioglu U., Baumert B., Combs S.E., Kinhult S., Kros J.M., Marosi C., Metellus P., Radbruch A., Villa Freixa S.S., Brada M., Carapella C.M., Preusser M., Le Rhun E., Rudà R., Tonn J.C., Weber D.C., Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro‑Oncology (EANO). Neuro Oncol. 2017 Feb 1; 19(2): 162–174. doi: 10.1093/neuonc/now241.Peak S.J., Levin V.A. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22; 2: 97–104.Soffietti R., Abacioglu U., Baumert B., Combs S.E., Kinhult S., Kros J.M., Marosi C., Metellus P., Radbruch A., Villa Freixa S.S., Brada M., Carapella C.M., Preusser M., Le Rhun E., Rudà R., Tonn J.C., Weber D.C., Weller M. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro‑Oncology (EANO). Neuro Oncol. 2017 Feb 1; 19(2): 162–174. doi: 10.1093/neuonc/now241.Lévy C., Allouache D., Lacroix J., Dugué A.E., Supiot S., Campone M., Mahe M., Kichou S., Leheurteur M., Hanzen C., Dieras V., Kirova Y., Campana F., Le Rhun E., Gras L., Bachelot T., Sunyach M.P., Hrab I., Geffrelot J., Gunzer K., Constans J.M., Grellard J.M., Clarisse B., Paoletti X. REBECA: a phase I study of bevacizumab and whole‑brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014 Dec; 25(12): 2351–6. doi: 10.1093/annonc/mdu465.Berghoff A.S., Schur S., Füreder L.M., Gatterbauer B., Dieckmann K., Widhalm G., Hainfellner J., Zielinski C.C., Birner P., Bartsch R., Preusser M. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016 Mar 16; 1(2): e000024. doi: 10.1136/esmoopen‑2015‑000024.Ciric E., Sersa G. Radiotherapy in combination with vasculartargeted therapies. Radiol Oncol. 2010; 44(2): 67–78. doi: 10.2478/v10019‑010‑0025‑9.Berghoff A.S., Schur S., Füreder L.M., Gatterbauer B., Dieckmann K., Widhalm G., Hainfellner J., Zielinski C.C., Birner P., Bartsch R., Preusser M. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016 Mar 16; 1(2): e000024. doi: 10.1136/esmoopen‑2015‑000024.Grabham P., Sharma S. The effects of radiation on angiogenesis. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Jeon Y.S., Koh Y.C., Song S.W., Cho J., Lim S.D. Palliative resection of metastatic brain tumors previously treated by stereotactic radiosurgery. Brain Tumor Res Treat. 2016 Oct; 4(2): 116–123.Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Jeon Y.S., Koh Y.C., Song S.W., Cho J., Lim S.D. Palliative resection of metastatic brain tumors previously treated by stereotactic radiosurgery. Brain Tumor Res Treat. 2016 Oct; 4(2): 116–123.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastasis. Clin Cancer Res. 2010 Jan 1; 16(1): 26978. doi: 10.1158/1078‑0432.CCR‑09‑2439.Glitza I.C., Guha-Thakurta N., D'Souza N.M., Amaria R.N., McGovern S.L., Rao G., Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 Dec; 27(6): 580–584. doi: 10.1097/CMR.0000000000000389.Glitza I.C., Guha-Thakurta N., D'Souza N.M., Amaria R.N., McGovern S.L., Rao G., Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 Dec; 27(6): 580–584. doi: 10.1097/CMR.0000000000000389.Glitza I.C., Guha-Thakurta N., D'Souza N.M., Amaria R.N., McGovern S.L., Rao G., Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 Dec; 27(6): 580–584. doi: 10.1097/CMR.0000000000000389.Delishaj D., Ursino S., Pasqualetti F., Cristaudo A., Cosottini M., Fabrini M.G., Paiar F. Bevacizumab for the treatment of radiation‑induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017 Apr; 9(4): 273–280. doi: 10.14740/jocmr2936e.Delishaj D., Ursino S., Pasqualetti F., Cristaudo A., Cosottini M., Fabrini M.G., Paiar F. Bevacizumab for the treatment of radiation‑induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017 Apr; 9(4): 273–280. doi: 10.14740/jocmr2936e.Delishaj D., Ursino S., Pasqualetti F., Cristaudo A., Cosottini M., Fabrini M.G., Paiar F. Bevacizumab for the treatment of radiation‑induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017 Apr; 9(4): 273–280. doi: 10.14740/jocmr2936e.Delishaj D., Ursino S., Pasqualetti F., Cristaudo A., Cosottini M., Fabrini M.G., Paiar F. Bevacizumab for the treatment of radiation‑induced cerebral necrosis: a systematic review of the literature. J Clin Med Res. 2017 Apr; 9(4): 273–280. doi: 10.14740/jocmr2936e.Berghoff A.S., Preusser M. Anti‑angiogenic therapies in brain metastases. Memo. 2018; 11(1): 14–17. doi: 10.1007/s12254‑018‑0384‑2.Berghoff A.S., Preusser M. Anti‑angiogenic therapies in brain metastases. Memo. 2018; 11(1): 14–17. doi: 10.1007/s12254‑018‑0384‑2.Berghoff A.S., Preusser M. Anti‑angiogenic therapies in brain metastases. Memo. 2018; 11(1): 14–17. doi: 10.1007/s12254‑018‑0384‑2.Berghoff A.S., Preusser M. Anti‑angiogenic therapies in brain metastases. Memo. 2018; 11(1): 14–17. doi: 10.1007/s12254‑018‑0384‑2.Berghoff A.S., Sax C., Klein M., Furtner J., Dieckmann K., Gatterbauer B., Widhalm G., Rudas M., Zielinski C.C., Bartsch R., Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain‑ metastatic breast cancer: a case report. Breast Care (Basel). 2014 May; 9(2): 134–6. doi: 10.1159/000360930.Berghoff A.S., Sax C., Klein M., Furtner J., Dieckmann K., Gatterbauer B., Widhalm G., Rudas M., Zielinski C.C., Bartsch R., Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain‑ metastatic breast cancer: a case report. Breast Care (Basel). 2014 May; 9(2): 134–6. doi: 10.1159/000360930.Berghoff A.S., Sax C., Klein M., Furtner J., Dieckmann K., Gatterbauer B., Widhalm G., Rudas M., Zielinski C.C., Bartsch R., Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain‑ metastatic breast cancer: a case report. Breast Care (Basel). 2014 May; 9(2): 134–6. doi: 10.1159/000360930.Berghoff A.S., Sax C., Klein M., Furtner J., Dieckmann K., Gatterbauer B., Widhalm G., Rudas M., Zielinski C.C., Bartsch R., Preusser M. Alleviation of brain edema and restoration of functional independence by bevacizumab in brain‑ metastatic breast cancer: a case report. Breast Care (Basel). 2014 May; 9(2): 134–6. doi: 10.1159/000360930.Slotman B.J., Mauer M.E., Bottomley A., Faivre-Finn C., Kramer G.W., Rankin E.M., Snee M., Hatton M., Postmus P.E., Collette L., Senan S. Prophylactic Cranial Irradiation in Extensive Disease Small‑Cell Lung Cancer. J Clin Oncol. 2009 Jan 1; 27(1): 78–84. doi: 10.1200/JCO.2008.17.0746.Slotman B.J., Mauer M.E., Bottomley A., Faivre-Finn C., Kramer G.W., Rankin E.M., Snee M., Hatton M., Postmus P.E., Collette L., Senan S. Prophylactic Cranial Irradiation in Extensive Disease Small‑Cell Lung Cancer. J Clin Oncol. 2009 Jan 1; 27(1): 78–84. doi: 10.1200/JCO.2008.17.0746.Slotman B.J., Mauer M.E., Bottomley A., Faivre-Finn C., Kramer G.W., Rankin E.M., Snee M., Hatton M., Postmus P.E., Collette L., Senan S. Prophylactic Cranial Irradiation in Extensive Disease Small‑Cell Lung Cancer. J Clin Oncol. 2009 Jan 1; 27(1): 78–84. doi: 10.1200/JCO.2008.17.0746.Slotman B.J., Mauer M.E., Bottomley A., Faivre-Finn C., Kramer G.W., Rankin E.M., Snee M., Hatton M., Postmus P.E., Collette L., Senan S. Prophylactic Cranial Irradiation in Extensive Disease Small‑Cell Lung Cancer. J Clin Oncol. 2009 Jan 1; 27(1): 78–84. doi: 10.1200/JCO.2008.17.0746.Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E.2nd, Peters K.B., Allen K., Hoang J.K., Chang Z., Craciunescu O., Vredenburgh J.J., Friedman H.S., Kirkpatrick J.P. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5): 873–9. doi: 10.1016/j.ijrobp.2013.04.029.Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E.2nd, Peters K.B., Allen K., Hoang J.K., Chang Z., Craciunescu O., Vredenburgh J.J., Friedman H.S., Kirkpatrick J.P. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5): 873–9. doi: 10.1016/j.ijrobp.2013.04.029.Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E.2nd, Peters K.B., Allen K., Hoang J.K., Chang Z., Craciunescu O., Vredenburgh J.J., Friedman H.S., Kirkpatrick J.P. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5): 873–9. doi: 10.1016/j.ijrobp.2013.04.029.Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E.2nd, Peters K.B., Allen K., Hoang J.K., Chang Z., Craciunescu O., Vredenburgh J.J., Friedman H.S., Kirkpatrick J.P. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: A prospective trial. Int J Radiat Oncol Biol Phys. 2013 Aug 1; 86(5): 873–9. doi: 10.1016/j.ijrobp.2013.04.029.Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E. 2nd, McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1): 63–70. doi: 10.1007/s11060‑012‑0861‑0.Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E. 2nd, McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1): 63–70. doi: 10.1007/s11060‑012‑0861‑0.Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E. 2nd, McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1): 63–70. doi: 10.1007/s11060‑012‑0861‑0.Lou E., Sumrall A.L., Turner S., Peters K.B., Desjardins A., Vredenburgh J.J., McLendon R.E., Herndon J.E. 2nd, McSherry F., Norfleet J., Friedman H.S., Reardon D.A. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1): 63–70. doi: 10.1007/s11060‑012‑0861‑0.Peak S.J., Levin V.A. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22; 2: 97–104.Peak S.J., Levin V.A. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22; 2: 97–104.Peak S.J., Levin V.A. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22; 2: 97–104.Peak S.J., Levin V.A. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22; 2: 97–104.Lévy C., Allouache D., Lacroix J., Dugué A.E., Supiot S., Campone M., Mahe M., Kichou S., Leheurteur M., Hanzen C., Dieras V., Kirova Y., Campana F., Le Rhun E., Gras L., Bachelot T., Sunyach M.P., Hrab I., Geffrelot J., Gunzer K., Constans J.M., Grellard J.M., Clarisse B., Paoletti X. REBECA: a phase I study of bevacizumab and whole‑brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014 Dec; 25(12): 2351–6. doi: 10.1093/annonc/mdu465.Lévy C., Allouache D., Lacroix J., Dugué A.E., Supiot S., Campone M., Mahe M., Kichou S., Leheurteur M., Hanzen C., Dieras V., Kirova Y., Campana F., Le Rhun E., Gras L., Bachelot T., Sunyach M.P., Hrab I., Geffrelot J., Gunzer K., Constans J.M., Grellard J.M., Clarisse B., Paoletti X. REBECA: a phase I study of bevacizumab and whole‑brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014 Dec; 25(12): 2351–6. doi: 10.1093/annonc/mdu465.Lévy C., Allouache D., Lacroix J., Dugué A.E., Supiot S., Campone M., Mahe M., Kichou S., Leheurteur M., Hanzen C., Dieras V., Kirova Y., Campana F., Le Rhun E., Gras L., Bachelot T., Sunyach M.P., Hrab I., Geffrelot J., Gunzer K., Constans J.M., Grellard J.M., Clarisse B., Paoletti X. REBECA: a phase I study of bevacizumab and whole‑brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014 Dec; 25(12): 2351–6. doi: 10.1093/annonc/mdu465.Lévy C., Allouache D., Lacroix J., Dugué A.E., Supiot S., Campone M., Mahe M., Kichou S., Leheurteur M., Hanzen C., Dieras V., Kirova Y., Campana F., Le Rhun E., Gras L., Bachelot T., Sunyach M.P., Hrab I., Geffrelot J., Gunzer K., Constans J.M., Grellard J.M., Clarisse B., Paoletti X. REBECA: a phase I study of bevacizumab and whole‑brain radiation therapy for the treatment of brain metastasis from solid tumours. Ann Oncol. 2014 Dec; 25(12): 2351–6. doi: 10.1093/annonc/mdu465.Ciric E., Sersa G. Radiotherapy in combination with vasculartargeted therapies. Radiol Oncol. 2010; 44(2): 67–78. doi: 10.2478/v10019‑010‑0025‑9.Ciric E., Sersa G. Radiotherapy in combination with vasculartargeted therapies. Radiol Oncol. 2010; 44(2): 67–78. doi: 10.2478/v10019‑010‑0025‑9.Ciric E., Sersa G. Radiotherapy in combination with vasculartargeted therapies. Radiol Oncol. 2010; 44(2): 67–78. doi: 10.2478/v10019‑010‑0025‑9.Ciric E., Sersa G. Radiotherapy in combination with vasculartargeted therapies. Radiol Oncol. 2010; 44(2): 67–78. doi: 10.2478/v10019‑010‑0025‑9.Grabham P., Sharma S. The effects of radiation on angiogenesis. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Grabham P., Sharma S. The effects of radiation on angiogenesis. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Grabham P., Sharma S. The effects of radiation on angiogenesis. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Grabham P., Sharma S. The effects of radiation on angiogenesis. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Mazeron R., Anderson B., Supiot S., Paris F., Deutsch E. Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Vasc Cell. 2013 Oct 26; 5(1): 19. doi: 10.1186/2045‑824X‑5‑19.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastasis. Clin Cancer Res. 2010 Jan 1; 16(1): 26978. doi: 10.1158/1078‑0432.CCR‑09‑2439.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastasis. Clin Cancer Res. 2010 Jan 1; 16(1): 26978. doi: 10.1158/1078‑0432.CCR‑09‑2439.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastasis. Clin Cancer Res. 2010 Jan 1; 16(1): 26978. doi: 10.1158/1078‑0432.CCR‑09‑2439.Besse B., Lasserre S.F., Compton P., Huang J., Augustus S., Rohr U.P. Bevacizumab safety in patients with central nervous system metastasis. Clin Cancer Res. 2010 Jan 1; 16(1): 26978. doi: 10.1158/1078‑0432.CCR‑09‑2439.

The authors declare that there are no conflicts of interest present.